Hepion tumbles after discontinuing trial for fatty liver disease treatment
19/04/2024 22:34
** Shares of drug developer Hepion Pharmaceuticals HEPA.O
fall 33.8% to $1.30 in extended trading
** Company says it is winding down a mid-stage trial
evaluating the drug rencofilstat for the treatment of a fatty
liver disease known as non-alcoholic steatohepatitis
** There is low probability of generating relevant efficacy
data given its current cash resources - Hepion
** Company is continuing to explore strategic alternatives
** Up to last close, stock down 86.4% in last 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement